MSD France
12
4
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
8.3%
1 terminated/withdrawn out of 12 trials
75.0%
-11.5% vs industry average
17%
2 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
Role: collaborator
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Role: collaborator
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Role: collaborator
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Role: collaborator
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Role: collaborator
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
Role: collaborator
Hybrid Prehabilitation Before Thoracic Surgery
Role: collaborator
Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock.
Role: collaborator
Using Reconsolidation Blockade to Treat Trauma Related Disorders After Paris Attacks: an Effectiveness Study
Role: collaborator
Integrated Care Pathway in Oncology (PASSION)
Role: collaborator
Oral Chemotherapy and Quality of Care
Role: collaborator
Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease
Role: collaborator
All 12 trials loaded